Search results

Page results

• Advice and guidance service at UCLH

  UCLH is continuing to scale up the number of services that offer Advice & Guidance, as well as identifying various improvements within the existing Advice & Guidance service. Over the last few months, UCLH has introduced 5 new specialties to the service, with additional specialties due to go live shortly.

• RESPOND services for healthcare professionals

  RESPOND – Information for healthcare professionals and services working with asylum seekers

• Having proton beam therapy under general anaesthetic: information for children aged 1- 4

  Having proton beam therapy under general anaesthetic: information for children aged 1- 4 patient information

• Having proton beam therapy under general anaesthetic: information for children aged 5-8

  Having proton beam therapy under general anaesthetic: information for children aged 5-8 patient information

• Pain Management Centre at NHNN

  UCLH Pain Management Centre is a nationally recognized centre of excellence for people with longstanding pain.

• Clinical Research Facility at UCLH awarded £10 million

  The Clinical Research Facility at UCLH has been awarded £10 million in funding to deliver cutting edge early phase health research in areas including cancer and dementia.

• UCLH top trust to work at in London – and third best in the country

  Our staff have rated UCLH as the top trust in London to work at, and the third best in the country, during what has been another incredibly challenging year.

• London hospitals partner up to run event for children and young people with sickle cell disorder at the Tottenham Hotspur Stadium

  North Mid, UCLH and Whittington Health are running a fun, uplifting, informative event for people with sickle cell on Saturday 25th June 2022.

• Meet the maternity teams

  While you're pregnant you will have a nominated professional lead which will be a midwife or an obstetrician.

• First participant in Europe joins new myeloma trial at UCLH

  UCLH has recruited the first patient in Europe for an early phase trial of a potential new medicine for patients that have a specific sub-type of multiple myeloma (MM), a type of bone marrow cancer.